Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy

被引：4
作者：
Ferraro, Francesca [1 ]
Gruszczynska, Agata
Ruzinova, Marianna B. [1 ,2 ]
Miller, Christopher A. [1 ]
Percival, Mary Elizabeth [3 ,4 ]
Uy, Geoffrey L. [1 ]
Pusic, Iskra [1 ]
Jacoby, Meagan A. [1 ]
Christopher, Mathew J. [1 ]
Kim, Miriam Y. [1 ]
Westervelt, Peter [1 ]
Cashen, Amanda F. [1 ]
Schroeder, Mark A. [1 ]
DiPersio, John F. [1 ]
Abboud, Camille N. [1 ]
Wartman, Lukas D. [1 ]
Gao, Feng [5 ]
Link, Daniel C. [1 ]
Ley, Timothy J. [1 ]
Welch, John S. [1 ]
机构：
[1] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA
[3] Univ Washington, Div Hematol, Dept Internal Med, Sch Med, Seattle, WA USA
[4] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA
[5] Washington Univ, Div Publ Hlth Sci, Dept Surg, Sch Med, St Louis, MO USA
来源：
HAEMATOLOGICA | 2022年 / 107卷 / 07期
关键词：
TP53; MUTATIONS; IMPACT; AML;
D O I：
10.3324/haematol.2021.280153
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1709 / 1713
页数：5
相关论文
共 50 条
  • [21] The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia
    Shallis, Rory M.
    Stahl, Maximilian
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    Testa, Ugo
    Walter, Roland B.
    HEMATO, 2021, 2 (04): : 748 - 763
  • [22] Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
    Shahzad, Moazzam
    Tariq, Ezza
    Chaudhary, Sibgha Gull
    Anwar, Iqra
    Iqbal, Qamar
    Fatima, Huda
    Abdelhakim, Haitham
    Ahmed, Nausheen
    Balusu, Ramesh
    Hematti, Peiman
    Singh, Anurag K.
    McGuirk, Joseph P.
    Mushtaq, Muhammad Umair
    LEUKEMIA & LYMPHOMA, 2022, 63 (14) : 3409 - 3417
  • [23] TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Welch, J. S.
    Petti, A. A.
    Miller, C. A.
    Fronick, C. C.
    O'Laughlin, M.
    Fulton, R. S.
    Wilson, R. K.
    Baty, J. D.
    Duncavage, E. J.
    Tandon, B.
    Lee, Y-S
    Wartman, L. D.
    Uy, G. L.
    Ghobadi, A.
    Tomasson, M. H.
    Pusic, I.
    Romee, R.
    Fehniger, T. A.
    Stockerl-Goldstein, K. E.
    Vij, R.
    Oh, S. T.
    Abboud, C. N.
    Cashen, A. F.
    Schroeder, M. A.
    Jacoby, M. A.
    Heath, S. E.
    Luber, K.
    Janke, M. R.
    Hantel, A.
    Khan, N.
    Sukhanova, M. J.
    Knoebel, R. W.
    Stock, W.
    Graubert, T. A.
    Walter, M. J.
    Westervelt, P.
    Link, D. C.
    DiPersio, J. F.
    Ley, T. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21) : 2023 - 2036
  • [24] Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
    Sperling, Adam S.
    Guerra, Veronica A.
    Kennedy, James A.
    Yan, Yuanqing
    Hsu, Joanne, I
    Wang, Feng
    Nguyen, Andrew T.
    Miller, Peter G.
    McConkey, Marie E.
    Barrios, Vanessa A. Quevedo
    Furudate, Ken
    Zhang, Linda
    Kanagal-Shamanna, Rashmi
    Zhang, Jianhua
    Little, Latasha
    Gumbs, Curtis
    Daver, Naval
    DiNardo, Courtney D.
    Kadia, Tapan
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Futreal, P. Andrew
    Ebert, Benjamin L.
    Takahashi, Koichi
    BLOOD, 2022, 140 (16) : 1753 - 1763
  • [25] Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax
    Kim, Kunhwa
    Maiti, Abhishek
    Loghavi, Sanam
    Pourebrahim, Rasoul
    Kadia, Tapan M.
    Rausch, Caitlin R.
    Furudate, Ken
    Daver, Naval G.
    Alvarado, Yesid
    Ohanian, Maro
    Sasaki, Koji
    Short, Nicholas J.
    Takahashi, Koichi
    Yilmaz, Musa
    Tang, Guilin
    Ravandi, Farhad
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Konopleva, Marina Y.
    CANCER, 2021, 127 (20) : 3772 - 3781
  • [26] Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia
    Khan, Niloufer
    Hantel, Andrew
    Knoebel, Randall W.
    Artz, Andrew
    Larson, Richard A.
    Godley, Lucy A.
    Thirman, Michael J.
    Liu, Hongtao
    Churpek, Jane E.
    King, Darren
    Odenike, Olatoyosi
    Stock, Wendy
    LEUKEMIA & LYMPHOMA, 2017, 58 (09) : 2127 - 2133
  • [27] Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
    Cluzeau, Thomas
    Loschi, Michael
    Fenaux, Pierre
    Komrokji, Rami
    Sallman, David A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [28] Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
    Daver, Naval G. G.
    Iqbal, Shahed
    Renard, Camille
    Chan, Rebecca J. J.
    Hasegawa, Ken
    Hu, Hao
    Tse, Preston
    Yan, Jiajun
    Zoratti, Michael J. J.
    Xie, Feng
    Ramsingh, Giridharan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [29] Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
    Bogdan Popescu
    Sheenu Sheela
    Julie Thompson
    Sophia Grasmeder
    Therese Intrater
    Christin B. DeStefano
    Christopher S. Hourigan
    Catherine Lai
    Clinical Hematology International, 2020, 2 (1) : 27 - 31
  • [30] Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia
    Westhus, Jonas
    Noppeney, Richard
    Schmitz, Christine
    Flasshove, Michael
    Duehrsen, Ulrich
    Hanoun, Maher
    ACTA HAEMATOLOGICA, 2020, 143 (05) : 438 - 445
12345